Thomas E. Stinchcombe

12.9k citations
216 papers · 7.1k · 3 hit papers · h-index 41

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Treatments and Mutations 109
    • Lung Cancer Diagnosis and Treatment 56
    • Lung Cancer Research Studies 50
    • Colorectal Cancer Treatments and Studies 23
    • Cancer Immunotherapy and Biomarkers 21
    • Cancer Treatment and Pharmacology 10

Thomas E. Stinchcombe

206 papers receiving 7.0k citations

Thomas E. Stinchcombe's Hit Papers

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study 2017 · 469 citations
4690+8+16Years since publication100200300400500

Peers

Thomas E. Stinchcombe
Comparison fields: 5 of 117
  • Oncology 2.8k
  • Pulmonary and Respiratory Medicine 2.9k
  • Cancer Research 582
  • Hematology 337
  • Pathology and Forensic Medicine 349
Replace Otilia Dalesio with:
Otilia Dalesio Netherlands
Daniel Morgensztern United States
Rogério Lilenbaum United States
Vassilis Georgoulias Greece
Philip Bonomi United States
Frédéric Rolland France
Carla M.L. van Herpen Netherlands
Noah M. Hahn United States
Alan B. Sandler United States
Élisabeth Quoix France
Thomas E. Stinchcombe relative to Otilia Dalesio Netherlands Otilia Dalesio's profile →
Citations per field
00.5×8.6×
Otilia Dalesio · 1×
Citations per year

Countries citing papers authored by Thomas E. Stinchcombe

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Stinchcombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Stinchcombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Stinchcombe more than expected).

Fields of papers citing papers by Thomas E. Stinchcombe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Stinchcombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Stinchcombe. The network helps show where Thomas E. Stinchcombe may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Stinchcombe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Stinchcombe Line = papers co-authored together Thomas E. Stinchcombe links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 216 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies
Hit paper breakdown →
2002585
2
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Hit paper breakdown →
2017469
3
Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
Hit paper breakdown →
2017314
4 2007265
5 2010199
6 2012189
7 2013187
8 2018184
9 2007172
10 2019156
11 2011154
12 2013146
13 2012130
14 2016118
15 2019117
16 2009117
17 200799
18 201793
19 201692
20 201989

About Thomas E. Stinchcombe

Thomas E. Stinchcombe is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 216 papers that have together received 7.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (109 papers), Lung Cancer Diagnosis and Treatment (56 papers), Lung Cancer Research Studies (50 papers), Colorectal Cancer Treatments and Studies (23 papers), Cancer Immunotherapy and Biomarkers (21 papers), Cancer Genomics and Diagnostics (19 papers), Radiomics and Machine Learning in Medical Imaging (14 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Oncology (2.8k citations), Pulmonary and Respiratory Medicine (2.9k citations), Cancer Research (582 citations), Hematology (337 citations) and Pathology and Forensic Medicine (349 citations). Thomas E. Stinchcombe has collaborated with scholars based in United States, Hong Kong and Canada. Frequent co-authors include Mark A. Socinski, Patrick J. Roberts, Everett E. Vokes, Carrie B. Lee, Dominic T. Moore, Vinicius Ernani, Julian Rosenman, Xiaofei Wang, Karen Kelly and Channing J. Der. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Lung Cancer, Clinical Lung Cancer and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact